Ari A, Levy Y, Segal N, et al. - A retrospective multi‐center case series performed in 5 tertiary care centers in Israel to test the safety and effectiveness of omalizumab (a monoclonal antibody to IgE) treatment for pediatric chronic spontaneous urticaria (CSU). The sample consisted of children < 18 years old diagnosed with recalcitrant CSU who were treated with omalizumab. Nineteen participants (11 F; 8 M) had CSU between the ages of 6 and 16.9 years. Children with recalcitrant CSU, including those < 12 years of age, respond well to standard‐dose, third‐line omalizumab therapy at rates comparable to adults. However, some instances can become non-responsive to ongoing care.